# Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload

> **NCT01254227** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Cardiac Iron Overload

## Interventions

- **DRUG:** Deferasirox and Deferoxamine

## Key facts

- **NCT ID:** NCT01254227
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254227, "Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01254227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*